NCT07299331 2025-12-23
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
Zhengzhou University
Phase NA Not yet recruiting
Clinical Trials
32 trialsNCT01829958 2025-05-06
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT06942507 2025-04-30
BRZ-WM
Peking Union Medical College Hospital
Phase NA Not yet recruiting
NCT06832228 2025-02-18
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Zhejiang Cancer Hospital
Phase NA Recruiting
NCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT06478472 2024-07-29
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
The First Affiliated Hospital of Xiamen University
Phase NA Recruiting
NCT05990985 2023-08-18
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
The First Hospital of Jilin University
Phase NA Not yet recruiting
NCT05809180 2023-04-20
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
The First Affiliated Hospital of Soochow University
Phase NA Recruiting
NCT05821192 2023-04-20
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
The First Hospital of Jilin University
Phase NA Unknown
NCT05784987 2023-03-27
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT05777369 2023-03-21
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT02652468 2022-01-05
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
University of Wisconsin, Madison
Phase NA Completed
NCT04432402 2020-06-16
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT00544219 2019-05-15
PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Swiss Cancer Institute
Phase NA Completed
NCT01702961 2018-12-19
Rituxan+BEAM
Baylor College of Medicine
Phase NA Completed
NCT00772668 2017-12-11
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
University of Miami
Phase NA Terminated
NCT00594815 2017-04-06
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT03022123 2017-01-16
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma
Hebei Medical University Fourth Hospital
Phase NA Unknown
NCT00648037 2016-02-01
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01230788 2014-12-01
Rituximab
Emory University
Phase NA Terminated
NCT01482754 2013-12-10
Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma
National University Hospital, Singapore
Phase NA Completed
NCT00387023 2013-11-18
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
M.D. Anderson Cancer Center
Phase NA Completed
NCT00651755 2013-07-02
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
M.D. Anderson Cancer Center
Phase NA Completed
NCT00082836 2013-01-17
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00476229 2012-08-07
Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
M.D. Anderson Cancer Center
Phase NA Completed
NCT00525876 2011-12-07
Non-Myeloablative Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase NA Completed
NCT00038844 2011-11-02
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
M.D. Anderson Cancer Center
Phase NA Completed
NCT00142155 2011-06-27
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase NA Completed
NCT00398372 2011-06-02
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Stanford University
Phase NA Completed
NCT00274794 2011-03-29
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
The Cleveland Clinic
Phase NA Completed
NCT00110006 2010-06-11
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT00689845 2009-07-08
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase NA Unknown